Literature DB >> 21635264

Topical anti-inflammatory effect of hypocholesterolaemic drugs.

Lívia Bracht1, Silvana Martins Caparroz-Assef, Thiago Ferreira dos Santos Magon, Alessandra Mileni Versuti Ritter, Roberto Kenji Nakamura Cuman, Ciomar Aparecida Bersani-Amado.   

Abstract

OBJECTIVES: The topical anti-inflammatory effect of simvastatin, atorvastatin, pravastatin, ezetimibe and combined ezetimibe + simvastatin was investigated, using the croton oil model of ear oedema in mice.
METHODS: Simvastatin, atorvastatin, pravastatin, ezetimibe and ezetimibe + simvastatin combination (dissolved in 20 µl of 70% acetone) were topically applied simultaneously with croton oil (200 µg/ear, dissolved in 20 µl of 70% acetone) at the inner surface of each ear. Ear oedema and myeloperoxidase activity, indicative of polymorphonuclear cell migration, were assessed 6 h after inflammatory stimuli. KEY
FINDINGS: It was found that statins can act as topical anti-inflammatories, but the pharmacological effect is dependent on statin polarity. At 0.3 mg/ear inhibition of ear oedema was 79%, 67% and 40% for simvastatin, atorvastatin and pravastatin, respectively. Simvastatin and atorvastatin also remarkably diminished myeloperoxidase activity, even at low concentrations (0.03 mg/ear). Pravastatin, the most polar statin, however, did not cause any reduction in ear oedema or myeloperoxidase activity at low doses. The order of topical anti-inflammatory activity was pravastatin < < < atorvastatinsimvastatin. Ezetimibe, another hypocholesterolaemic drug, also presented anti-inflammatory effects, inhibiting ear oedema by 64% at 0.3 mg/ear. However, when used in combination with simvastatin, no further beneficial effect was observed.
CONCLUSIONS: These results consistently support current evidence showing that statins can be used for treatment of dermatological disorders. Polarity of the molecule, however, is a factor that should be considered before recommending use.
© 2011 The Authors. JPP © 2011 Royal Pharmaceutical Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21635264     DOI: 10.1111/j.2042-7158.2011.01302.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  9 in total

1.  Anti-inflammatory and Antioxidant Activity of Nanoencapsulated Curcuminoids Extracted from Curcuma longa L. in a Model of Cutaneous Inflammation.

Authors:  Emanuele P Lima; Odinei H Gonçalves; Franciele Q Ames; Lidiane V Castro-Hoshino; Fernanda V Leimann; Roberto K N Cuman; Jurandir F Comar; Ciomar A Bersani-Amado
Journal:  Inflammation       Date:  2020-11-09       Impact factor: 4.092

2.  Inflammatory Mediators in Xanthelasma Palpebrarum: Histopathologic and Immunohistochemical Study.

Authors:  Maria S Govorkova; Tatyana Milman; Gui-Shuang Ying; Wei Pan; Rona Z Silkiss
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2018 May/Jun       Impact factor: 1.746

3.  Effects of Ezetimibe, Simvastatin, and their Combination on Inflammatory Parameters in a Rat Model of Adjuvant-Induced Arthritis.

Authors:  Carmem Patrícia Barbosa; Lívia Bracht; Franciele Queiroz Ames; Francielli Maria de Souza Silva-Comar; Rafael Prizon Tronco; Ciomar Aparecida Bersani-Amado
Journal:  Inflammation       Date:  2017-04       Impact factor: 4.092

4.  Effects of simvastatin, ezetimibe, and their combination on histopathologic alterations caused by adjuvant-induced arthritis.

Authors:  Carmem Patrícia Barbosa; Alessandra Milene Ritter; Lorena Gimenez da Silva; Renata Grespan; Roberto Kenji Nakamura Cuman; Luzmarina Hernandes; Ciomar Aparecida Bersani-Amado
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

5.  p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice.

Authors:  Yingli Wang; Xueyan Zhou; Kurun Oberoi; Robert Phelps; Ross Couwenhoven; Miao Sun; Amélie Rezza; Greg Holmes; Christopher J Percival; Jenna Friedenthal; Pavel Krejci; Joan T Richtsmeier; David L Huso; Michael Rendl; Ethylin Wang Jabs
Journal:  J Clin Invest       Date:  2012-05-15       Impact factor: 14.808

6.  Tomographic evaluation of the effect of simvastatin topical use on alveolar bone microarchitecture, pain and swelling after mandibular third molar extraction: a randomized controlled trial.

Authors:  Jiordanne Araújo Diniz; Davi da Silva Barbirato; Eduarda Helena Leandro do Nascimento; Andrea Dos Anjos Pontual; Ana Cláudia Amorim Gomes Dourado; José Rodrigues Laureano Filho
Journal:  Clin Oral Investig       Date:  2022-01-22       Impact factor: 3.573

7.  Preparation and Evaluation of Atorvastatin-Loaded Nanoemulgel on Wound-Healing Efficacy.

Authors:  Mohamed A Morsy; Rania G Abdel-Latif; Anroop B Nair; Katharigatta N Venugopala; Amira F Ahmed; Heba S Elsewedy; Tamer M Shehata
Journal:  Pharmaceutics       Date:  2019-11-13       Impact factor: 6.321

8.  A phase I/IIa trial of atorvastatin in Japanese patients with acute Kawasaki disease with coronary artery aneurysm: Study protocol of a multicenter, single-arm, open-label trial.

Authors:  Yo Murata; Reina Isayama; Shoko Imai; Kensuke Shoji; Mizuho Youndzi; Mami Okada; Masashi Mikami; Shinobu Kobayashi; Kevin Y Urayama; Tohru Kobayashi
Journal:  Contemp Clin Trials Commun       Date:  2022-01-20

9.  Atorvastatin Solid Lipid Nanoparticles as a Promising Approach for Dermal Delivery and an Anti-inflammatory Agent.

Authors:  Seyed Sadegh Shahraeini; Jafar Akbari; Majid Saeedi; Katayoun Morteza-Semnani; Shidrokh Abootorabi; Milad Dehghanpoor; Seyyed Sohrab Rostamkalaei; Ali Nokhodchi
Journal:  AAPS PharmSciTech       Date:  2020-09-25       Impact factor: 3.246

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.